Trump's 100% Drug Tariff Slammed as Threat to Patients and Innovation

On April 2, President Donald Trump announced a 100% tariff on patented pharmaceutical products and ingredients imported into the United States, claiming the policy addresses national security threats from foreign drug dependence. The pharmaceutical industry's response has been swift and scathing: this is a reckless move that will hurt patients, raise prices, and undermine American competitiveness against China.

The tariffs, imposed under Section 232 trade authority, take effect in 120 days for large companies and 180 days for smaller firms. Commerce Secretary Howard Lutnick justified the move by arguing that America's reliance on pharmaceutical imports threatens national security—a claim the industry flatly rejects.

"The reality is that any tariffs on America's medicines will raise costs, impede domestic manufacturing, and delay the development of new treatments—all while doing nothing to enhance our national security," said John Crowley, CEO of the Biotechnology Innovation Organization (BIO).

Carveouts Reveal Political Favoritism

The devil is in the details, and those details expose this policy as less about security and more about rewarding political allies. Companies that pledge to move production onshore face only a 20% tariff rate—and have four years to follow through before the full 100% kicks in. More tellingly, the 16 pharmaceutical giants that signed pricing agreements with the White House under the Most Favored Nation (MFN) framework—including Pfizer, Eli Lilly, and Merck—are completely exempt from tariffs until 2029.

Generics and biosimilars, which account for roughly 90% of American prescriptions, are not subject to the tariff at all. Neither are branded drugs from the European Union, Japan, Korea, Switzerland, Liechtenstein, or the United Kingdom, all of which have separate trade deals with the US.

According to ING senior economist Diederik Stadig, the countries actually hit by the 100% rate—Singapore, India, and China—do not currently export substantial volumes of branded pharmaceuticals to the United States. "The economic impact will therefore be negligible," Stadig wrote in a research note. "Rather, the tariff is geopolitical in nature and should be seen as a shot across the bow for more intense competition between the US and China in biotech and pharma."

China Looms Large in Trade War Calculations

Trump's tariff is part of a broader strategy to counter China's rapid rise in global drug development. According to GlobalData analysis from October 2025, China now accounts for one-fifth of global drug development, with one-third of all new molecules in global pipelines originating from Chinese companies. Western pharmaceutical giants are pouring billions into licensing deals with Chinese biotechs, reflecting the region's wealth of promising early-stage drugs.

"We believe that the next Pfizer will be Chinese rather than American or European," Stadig said. "US policymakers on both sides of the aisle have realised that China is a real threat to US dominance in biopharmaceutical innovation."

In January 2026, Trump enacted the BIOSECURE Act, which prevents certain Chinese biotechs and manufacturers from accessing US funding or collaborating with domestic pharma companies that use federal dollars. The new tariff is another weapon in that arsenal.

The administration points to supply chain vulnerabilities as justification. According to the FDA, approximately 53% of patented pharmaceutical products distributed in the US are manufactured abroad. Trump argued in a statement that life-saving medications could be limited during global supply chain disruptions caused by geopolitical or economic crises—a concern heightened by ongoing conflict in the Middle East.

Industry: Tariffs Will Backfire

Pharmaceutical trade groups are unanimous in their condemnation. They argue that tariffs will divert resources away from research and development, weaken American biotech against Chinese competitors, and ultimately harm patients.

"Tariffs divert scarce resources away from research and development, weaken American biotech against China's rising industry, and ultimately, harm the health and economic well-being of Americans," Crowley said.

Stephen Ubl, CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), echoed that sentiment: "We need smart policies to ensure that the US remains the best place in the world to discover and manufacture affordable, lifesaving medicines. Tariffs will undermine this important goal."

The policy's exemptions for politically connected companies and its negligible economic impact on actual drug imports suggest this is less about securing supply chains and more about flexing geopolitical muscle. Meanwhile, the pharmaceutical industry warns that patients will pay the price—both in higher costs and delayed access to new treatments—for a policy that solves nothing.